Shanghai Huanghai Pharmaceutical Co., Ltd. (referred to as Shanghai Huanghai Pharma), a subsidiary of Shanghai Baheal Pharmaceutical Co., Ltd. (referred to as Baheal Pharma), has been honored with the 2024 Excellence in Pharmaceutical Quality Award at the recent 2nd Pharmaceutical High-Quality Development Industry Conference and China Pharmaceutical Managers Annual Meeting. This award is a recognition of Shanghai Huanghai Pharma's outstanding quality management system and superior product quality.

The award selection process was thorough, assessing various factors including regional development, regulatory data, market feedback, quality management maturity, and regional exemplary influence. Through a series of objective, fair, and impartial procedures, including material review, joint nomination, and deliberative voting, a total of 20 companies were ultimately chosen.

Quality is the lifeline of pharmaceuticals. Shanghai Huanghai Pharma has been honored with this prestigious award, recognizing its commitment to technological innovation, quality excellence, continuous improvement, safety and efficacy, integrity, and customer satisfaction. This not only marks another milestone in drug quality control but also serves as a powerful testament to the company's overall strength and industry influence, highlighting its outstanding contributions to the high-quality development of the traditional Chinese medicine industry.

Shanghai Huanghai Pharma, as an innovative platform for the research, development, and production of traditional Chinese medicine (TCM), boasts a comprehensive management system that covers the entire life-cycle of its products. The company implements a holistic approach to quality control, involving all employees, all aspects, and every stage of the production process, enhancing the effectiveness of product quality control and traceability. Guided by the modern TCM research and production philosophy of "Diagnosable diseases, controllable quality, and verifiable efficacy," the company has established a digitalized production workshop for modern compound TCM, built to FDA quality control standards and aimed at the international market. Their liver fibrosis reversal product, Fuzheng Huayu, is the only TCM in the field of liver diseases to have received FDA approval and completed Phase II clinical trials in the United States. Looking ahead, the company will continue to upgrade from "manufacturing" to "intelligent manufacturing," continually improving product processes and competitive advantages, advancing the construction of a digital and intelligent factory, and setting a benchmark for smart manufacturing.

Shanghai Huanghai Pharma's parent company, Baheal Pharma, is an innovative pharmaceutical enterprise focused on the modernization of traditional Chinese medicine (TCM) and the development and production of controlled-release formulations. Baheal Pharma, a subsidiary of the publicly listed Baheal Medical (SZ.301015)，a rising star in China's national pharmaceutical industry, always adheres to the principle of "International Quality, Health Care." The company prioritizes independent innovation and research, guided by modern medical theories, and specializes in advanced controlled-release formulation technologies to develop innovative products that integrate TCM and Western medicine, all with proprietary intellectual property. In addition, Baheal Pharma is forging strong partnerships with national research institutions to advance the innovation of high-end formulations, modernized traditional Chinese medicines, and pioneering natural drug products.

Looking ahead, Baheal Pharma is poised to capitalize on the dual avenues of innovation and creation within China’s pharmaceutical industry. By advancing both modern traditional Chinese medicine and high-end pharmaceutical formulations, the company aspires to continually invigorate the intrinsic dynamism and growth potential of the healthcare sector. Through relentless technological innovation, Baheal Pharma is dedicated to optimizing healthcare outcomes and making substantial contributions to global health and well-being.